Oncology Discovery Lead: Cancer Cell Vulnerabilities

Servier Group; Saclay; Sur place; EUR 80 000 - 120 000; Plein temps

Résumé du poste

The Servier Group, based in Saclay, France, is seeking a Project Leader for Cancer Cell Vulnerabilities within its Oncology team. This role involves leading drug discovery programs and integrating innovative technologies to enhance small molecule therapeutic development.

With a Ph.D. and extensive experience in oncology drug discovery, you will oversee projects from concept to Preclinical Candidate nomination, ensuring scientific excellence and strategic direction.

If you have a passion for driving impactful research, join us in our mission to advance therapeutic progress for patients.

Qualifications

• 7–10+ years of experience in oncology small molecule drug discovery.
• Proven track record in leading discovery programs.
• Strong understanding of tumor biology and translational research.

Responsabilités

• Lead oncology discovery programs from target identification to PCC nomination.
• Define and drive scientific and translational strategy.
• Chair and lead cross-functional Core Team.

Connaissances

Project management

Oncology small molecule drug discovery

Cross-functional leadership

Scientific strategy development

Risk-based decision-making

Cancer biology

Formation

Ph.D. in Cancer Biology, Cell or Molecular Biology, Pharmacology

Outils

AI-enabled approaches

Description du poste

The Servier Group, based in Saclay, France, is seeking a Project Leader for Cancer Cell Vulnerabilities within its Oncology team. This role involves leading drug discovery programs and integrating innovative technologies to enhance small molecule therapeutic development.

With a Ph.D. and extensive experience in oncology drug discovery, you will oversee projects from concept to Preclinical Candidate nomination, ensuring scientific excellence and strategic direction.

If you have a passion for driving impactful research, join us in our mission to advance therapeutic progress for patients.